Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma

Yong Zhang¹, Xiaoyan Hu¹, Yue Hu¹, Kai Teng², Kai Zhang¹, Yamei Zheng³, Xiaohua Hong¹, Kunwu Yu⁴, Yan Wang⁵ and Li Liu¹*

Abstract

Background: Agonistic CD40 antibodies have been demonstrated to activate antigen-presenting cells (APCs) and enhance antitumour T cell responses, thereby providing a new therapeutic option in cancer immunotherapy. In agonistic CD40 antibody-mediated inflammatory responses, a novel subset of E-cadherin + dendritic cells (DCs) has been identified, and little is known about the role of these DCs in tumour immunity. This study investigated the effect of anti-CD40-mediated inflammatory E-cadherin + DCs in murine Lewis lung carcinoma (LLC).

Methods: The phenotype and characteristics of anti-CD40-mediated inflammatory E-cadherin + DCs isolated from the anti-CD40 model were assessed in vitro. The antitumour activity of E-cadherin + DCs were evaluated in vivo by promoting the differentiation of effector CD4+ T cells, CEA-specific CD8+ T cells and CD103+ CD8+ T cells and assessing their resistance to tumour challenge, including variations in tumour volume and survival curves.

Results: Here, we demonstrated that anti-CD40-mediated E-cadherin + inflammatory DCs accumulate in the lungs of Rag1 KO mice and were able to stimulate naïve CD4+ T cells to induce Th1 and Th17 cell differentiation and polarisation and to inhibit regulatory T cell and Th2 responses. Importantly, with the adoptive transfer of E-cadherin + DCs into the Lewis lung cancer model, the inflammatory DCs increased the Th1 and Th17 cell responses and reduced the Treg cell and Th2 responses. Interestingly, following the injection of inflammatory E-cadherin + DCs, the CD103+ CD8+ T cell and CEA-specific CD8+ T cell responses increased and exhibited potent antitumour immunity.

Conclusions: These findings indicate that anti-CD40-induced E-cadherin + DCs enhance T cell responses and antitumour activity in non-small cell lung cancer (NSCLC)-bearing mice and may be used to enhance the efficacy of DC-based peptide vaccines against NSCLC.

Keywords: E-cadherin, Dendritic cell, T cell, Lung cancer, Activity
**Introduction**

CD40 is a tumour necrosis factor receptor superfamily member that is expressed on antigen-presenting cells (APCs) such as dendritic cells (DC), B cells, monocytes and some tumour cells. Recently, agonistic CD40 antibodies were applied in clinical trials targeting advanced pancreatic ductal adenocarcinoma (CP-870,893) and diffuse large B cell lymphoma (dacetuzumab and Chi Lob 7/4). The CD40 agonistic antibody has displayed excellent anti-tumour activity in the patients in these trials [1,2]. Many subsets of DCs exist in the agonistic CD40 antibody-mediated tumour microenvironment or under sterile inflammatory response conditions. However, the mechanism and function of CD40-mediated inflammatory DCs in cancer immunity are unknown.

In CD40 agonistic antibody-mediated inflammatory responses, a novel subset of E-cadherin + DCs has been identified. Although CD40 signalling is critical for the differentiation of inflammatory monocytes into E-cadherin + inflammatory DCs and the promotion of anti-CD40-mediated colitis has been confirmed in Rag1 KO mice [3], little is known regarding the role of E-cadherin + inflammatory DCs in tumour immunity.

Precisely how inflammatory DCs with tumour antigen peptides can induce a T cell response in tumour immunity is poorly understood. Here, we identified the inflammatory E-cadherin + DCs that accumulate in the lung during the anti-CD40 antibody-mediated inflammatory response. The phenotypes of these DCs are the same as those of spleen-derived inflammatory E-cadherin + DCs that are present during anti-CD40-mediated colitis. The agonistic CD40 mAb has not been universally accepted as a novel cancer therapy. Concerns include cytokine release syndromes, autoimmune reactions [4], thrombembolic syndromes, hyperimmune stimulation leading to release syndromes, autoimmune reactions [4], thrombosis, thromboembolic syndromes, hyperimmune stimulation leading to release syndromes, autoimmune reactions [4], thrombosis, autoimmune reactions [4], thrombosis, autoimmune reactions [4], thrombosis, autoimmune reactions [4], thrombosis, autoimmune reactions [4], thrombosis, autoimmune reactions [4], thrombosis, autoimmune reactions [4], thrombosis, autoimmune reactions [4], and tumour angiogenesis, possibly as a result of the CD40-dependent activation of tumour endothelial cells [7]. These effects may cause unacceptable toxicity or promote tumour growth [8]. This study aimed to investigate the effects of anti-CD40-induced E-cadherin + DCs on the T cell response and antitumour activity in the tumour microenvironment. We found that inflammatory E-cadherin + DCs were present only in anti-CD40-mediated innate immunity, not innate, adoptive and tumour immunity. Our study will address the disadvantages of agonistic CD40 mAb in tumour therapy and may provide novel therapeutic strategies, as well as explain the pathogenesis of non-small cell lung cancer (NSCLC).

**Materials and methods**

Additional materials and methods can be found in the Additional file 1.
medium supplemented with 10% FBS, IL-2 (100 IU/ml, R&D Systems), plate-bound anti-CD3 and soluble anti-CD28 (5 μg/ml each, eBioscience) [11], either under Th1, Th2 and Th17 conditions for 96 h or Treg conditions for 5 days. Then, the Th1, Th2 and Th17 cells and the relevant cytokines were analysed at 72 h and 96 h. Treg cells and the relevant cytokines were analysed at 72 h and on day 5. Cell supernatants were collected and stored at −80°C for subsequent analysis of CD4+ T cell differentiation using the mouse Th1/Th2/Th17/Th22 13-plex kit (eBioscience) and the mouse TGF-β1 simplex kit (eBioscience). For Th1, Th2 and Th17 effector T cell polarisation analysis, multiplying system cells were collected on day 3 and analysed with the mouse Th1/Th2/Th17 phenotyping kit (BD Biosciences); for the Treg cell analysis, the mouse Th17/ Treg phenotyping kit (BD Biosciences) was used after multiplying system cells collected at day 5.

For CD8+ T cell differentiation analysis, 2.3 × 10^5 E-cadherin + or E-cadherin- DCs that were cultured with 5 μg/ml CEA526-533 peptide (Invitrogen) for 24 h were cultured with 3 × 10^5 sorted naive CD8+ T cells, anti-CD3 (1 μg/ml) and anti-CD28 (5 μg/ml). The naive CD8+ T cells cultured with anti-CD3 (1 μg/ml) and anti-CD28 (5 μg/ml) (no DCs) were considered as a control. At 48 h, the supernatant was collected to detect IFN-γ secretion using the mouse IFN-γ ELISA Kit (R&D systems).

**In vivo experiments**

For the in vivo experiments, 5 × 10^5 E-cadherin + CD11c<sup>high</sup>CD103<sup>−</sup>CD4-7AAD- DCs from the spleens of the Rag1<sup>−/−</sup> anti-CD40 mouse model were transferred into the orthotopic or subcutaneous lung tumour model by tail vein injection at day 7, day 14 or day 21 after the tumour model was established (the day of tumour cell injection was day 0). The same number of E-cadherin-CD11c<sup>high</sup>CD103<sup>−</sup>CD4<sup>−</sup>7AAD- DCs and 200 μl of PBS were injected as controls. The E-cadherin + and E-cadherin- CD11c<sup>high</sup> cell fractions were cultured with 5 μg/ml CEA526-533 peptide (Invitrogen) for 24 h prior to i.v. injection into the LLC tumour-bearing mice. At day 28, the orthotopic lung tumour-bearing mice were sacrificed, and the tumour tissues were harvested and prepared to investigate the effects of the E-cadherin + DCs on the helper T cell response using PCR and western blotting analyses. Lung tissue from orthotopic tumour-bearing mice was also prepared as a cell suspension to assay CD103 expression in CD8+ T cells. Spleen lymphocytes of orthotopic tumour-bearing mice were stained for tetramer staining.

**Statistical analyses**

All data are expressed as the mean ± SD. Significant results were assessed using analysis of variance. Statistical significance between alues was determined using Student’s t test, and a statistically significant difference between two test groups was defined as P < 0.05.

**Results**

**The phenotype of inflammatory E-cadherin + DCs in the lung**

A subset of E-cadherin + inflammatory DCs has been identified in an anti-CD40 colitis model [3]. However, the presence of these CD40-mediated E-cadherin + DCs in the lung and their phenotype are unknown. To investigate the expression of E-cadherin in lung dendritic cells in the presence of different immune responses, we harvested lung tissue from the Lewis orthotopic lung cancer model, C57BL/6, Rag1 KO mice and Rag1 KO mice exposed to an anti-CD40 antibody, respectively. Interestingly, the fluorescence levels of E-cadherin and CD11c in the lung tumour were low, with E-cadherin only expressed in a minor fraction of the lung tissue of C57BL/6 mice, whereas the expression of E-cadherin and CD11c in the lung tissue of Rag1 KO mice exposed to an anti-CD40 antibody was increased and significantly greater than their expression in the Lewis orthotopic lung cancer model and C57BL/6 mice (Figure 1A). We then analysed whether E-cadherin was expressed in lung DCs undergoing a CD40 mAb-mediated inflammatory response. We showed that a minor subset of CD11c<sup>high</sup> cells expressed E-cadherin in the lung, and approximately 11.3% of CD11c<sup>high</sup> cells expressed E-cadherin during the CD40 mAb-mediated inflammatory response. The majority of lung-derived E-cadherin + and E-cadherin- DCs expressed high levels of CD11b and CD103 while expressing CD4 at low levels. The majority of E-cadherin + DCs expressed CD103 under steady-state conditions [3], whereas the phenotype of E-cadherin + DCs in the lung under anti-CD40 conditions was the same as that of E-cadherin + DCs in the spleen (E-cadherin + CD11c<sup>high</sup>CD11b<sup>high</sup>CD103-CD4-) (Figure 1B). These findings suggest that the phenotype of lung inflammatory E-cadherin + DCs mimics that of E-cadherin + DCs in the lung cancer model and C57BL/6 mice (Figure 1A).

**The effects of E-cadherin + DCs on effector T cells (Th1 and Th2)**

Inflammatory E-cadherin + BM-DCs isolated from the CD4 + CD45RB<sup>high</sup>CD11b<sup>high</sup>T cell colitis model promote the Th17 response, whereas the Th1 response is not significantly altered from that in response to E-cadherin- BM-DCs [3]. To investigate the effects of CD40-mediated E-cadherin + DCs isolated from the spleens of anti-CD40 Rag1 KO mice on the Th1 and Th2 responses in the tumour micro-environment, naive CD4+ T cells were incubated for 96 h with E-cadherin + DCs or E-cadherin- DCs, both of which had been pre-incubated with 5 μg/ml CEA421-435...
peptide for 24 h. We observed that the E-cadherin + DCs increased the number of IFN-γ + CD4+ T cells and decreased the number of IL-4 + CD4+ T cells (Figure 2A), whereas extracellularly, IFN-γ and IL-2 secretion was greater than that of the E-cadherin- DC group. However, the secretion of IL-4, IL-5 and IL-13 decreased when compared with that of E-cadherin- DCs. Interestingly, in the E-cadherin + DCs, the secretion of IL-6 was significantly greater than that in the E-cadherin- DCs (Figure 2B). These data suggest that CD40-mediated inflammatory E-cadherin + DCs are able to promote the Th1 response and inhibit the Th2 response in tumour immunity when carrying the CEA peptide.

E-cadherin + DCs promote the Th17 response and decrease the percentage of Treg cells

The differentiation of Th17 cells was enhanced by E-cadherin + DCs in vivo. However, no differences were observed in the frequency of Treg cells compared with E-cadherin- BM-DCs [3]. In light of these findings, we examined the effects of the CD40-mediated E-cadherin + DCs on Th17 and Treg cells. The sorted naive CD4+ T cells were incubated with the CEA421-435 peptide. We showed that the addition of E-cadherin + DCs led to a profound upregulation of Th17 polarisation and reduced the polarisation of Treg cells. Changes in the same functions of Th17 cells and Treg cells were weak in the E-cadherin- DC controls (Figure 3A). We then analysed the secretion of IL-17, IL-10 and TGF-β in the presence or absence of anti-CD40 spleen-derived E-cadherin + DCs. Regarding the secretion of Th17 and Treg cell cytokines, a similar difference was observed between the E-cadherin + DCs and E-cadherin- DCs. Following the addition of E-cadherin + DCs, the secretion of IL-17 was greater than that of the E-cadherin- DC controls; nevertheless, the secretion of IL-10 and TGF-β was decreased compared with the E-cadherin- DCs (Figure 3B). We concluded that CD40-mediated E-cadherin DCs are potent inducers of Th17 cell-mediated responses and suppressors of Treg cell differentiation when carrying the CEA peptide in vitro.

E-cadherin + DCs enhance the T cell response in orthotopic Lewis lung cancer model

We have shown that CD40-mediated inflammatory E-cadherin + DCs enhance T cell responses in tumour immunity in vitro. However, T cell responses are typically inhibited in tumour immunity, especially in effector CD4+ T cells (Th1, Th2 and Th17 responses). Inflammatory DCs
have an excellent ability to activate naive T cells. To assay the effect of inflammatory E-cadherin + DCs on the T cell response and antitumour activity in vivo, we transferred $5 \times 10^5$ E-cadherin + DCs loaded with the CEA526-533 peptide into an orthotopic lung tumour model by tail-vein injection on days 7, 14, and 21 following tumour establishment. On day 28, five of the tumour-bearing mice were sacrificed, and the measured tumour volumes of those mice injected with E-cadherin + DCs were reduced relative to mice that received E-cadherin- DCs or the PBS control (Figure 4A-B). Interestingly, upon staining the tetramers of PE-CEA526-533/H-2Db in the spleen lymphocytes of tumour-bearing mice, we found that the percentage of CD8+ CEA526-533 tetramer + T cells was greater than that in mice that received E-cadherin- DCs and the PBS control mice (Figure 4C). We has observed the similar variation of CD8+ CEA526-533 tetramer + T cells on day14 and day 21 (Additional file 1: Figure S5). CD103 + CD8+ T cells have been shown to have an effective role in inhibiting breast cancer and glioma progression [12,13]. However, the effects of these DCs on lung CD103 + CD8+ T cells are unknown. In the lung cells of tumour-bearing mice injected with E-cadherin + DCs, we showed that the percentage of CD8+ T cells expressing CD103 was approximately 15.2%, whereas those of mice injected with E-cadherin- DCs or PBS were approximately 3.7% and 0.51%, respectively (Figure 4C), suggesting that CD40-mediated inflammatory E-cadherin + DCs enhance CEA-specific, CD8+ T cell responses and the expression of CD103 by CD8+ T cells in the lung tumour immune microenvironment.

To investigate the effect of CD40-mediated E-cadherin + DCs on CD4+ T lymphocytes of lung tumours, tumour tissue was harvested for qRT-PCR and western blotting. In this tumour immunity microenvironment model, with E-cadherin + DC treatment carrying the CEA526-533 antigen peptide, the transcription of T-bet and RORyt was enhanced compared with mice that received E-cadherin- DCs and the PBS control mice, whereas FOXP3 transcription was reduced (Figure 4D). The protein levels of IFN-γ and IL-17 were increased in the E-cadherin + DC group, whereas TGF-β was decreased. The transcription

Figure 2 Relationship between inflammatory E-cadherin + DCs and Th1 and Th2 cells. (A) The polarisation of Th1 cells with the percentage of CD4 + IFN-γ + T cells and the polarisation of Th2 cells with percentage of CD4 + IL-4 + T cells. Percentage of IFN-γ + CD4+ cells and IL-4 + CD4+ cells from the E-cadherin + DCs and E-cadherin- DCs groups, according to the gating of CD4+ T cells. (B) Secretion of cytokines from Th1 and Th2 cells. Cytokine secretion was measured in the supernatant using the FlowCytomix kit (eBioscience). The supernatant was harvested at 72 h and 96 h and then analysed for Th1 (IFN-γ) and Th2 (IL-4, IL-5, IL-6, IL-13). Each experiment was performed in triplicate. The asterisk indicates a significant difference between the two test groups, as analysed by Student’s t-test. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
of GATA3 and the protein level of IL-4 were reduced in the tumour tissue exposed to E-cadherin + DCs relative to that exposed to E-cadherin- DCs (Figure 4D-E).

The effects of E-cadherin + DCs on antitumour activity in Lewis lung cancer model
To further determine whether E-cadherin + DCs enhanced the antitumour activity and prolonged the survival time of tumour-bearing mice, we monitored tumour growth and the survival time of the subcutaneous model, as well as the survival time for the orthotopic lung tumour model (Figure 5A-C). Following transfer of E-cadherin + DCs loaded with the CEA526-533 peptide, the subcutaneous tumour volume decreased significantly compared with the E-cadherin- DC group. The E-cadherin + DCs prolonged the survival time of the subcutaneous and orthotopic lung tumour-bearing mice. However, no mice survived in the PBS-vaccinated group.

Discussion
A subset of DCs not found in the steady state occurs as a consequence of inflammation or antibody-mediated sterile inflammation. These DCs have been termed inflammatory DCs. Inflammatory monocytes are the main precursors of inflammatory DCs [14]. These precursors, such as Gr1 + CD115+ inflammatory monocytes, can differentiate into E-cadherin + DCs through GM-CSF mediation [3]. Although a few DCs express E-cadherin in normal mice, the inflammatory E-cadherin + DCs detected in the lungs of the lung tumour model are not detected. Here, we demonstrated that E-cadherin + DCs accumulated in the lung and spleen during CD40 mAb-mediated innate immunity, indicating that the provisions of the CD40 signalling pathway are sufficient to drive the accumulation of inflammatory DCs expressing E-cadherin.

Monocyte-derived inflammatory DCs play an early role in adaptive immunity [15]. However, these cells have not been shown to prime naive T cells in vivo, and their functions in tumour immunity in vitro and in vivo are unknown. The differences in the activities of DC subsets on naive T cells depend on the phenotype of the DCs. CD8α+ DCs could play a role in tolerance induction and restrict the immune response, whereas CD8α- DCs could be stimulatory to the T cell response [16]. CD40-mediated inflammatory E-cadherin + DCs do not express CD8α and CD4. Surprisingly, Pulendran et al. and Maldonado-Lopez et al. demonstrated that CD8α+ DCs lead to Th1 differentiation and that CD8α- DCs induce a Th2-type response [17,18]. Although E-cadherin+ and E-cadherin- BM-DCs failed to promote IFN-γCD4+ T cell generation, due to increased overall cell numbers, E-cadherin+, but not E-cadherin-, BM-DCs enhanced the Th1 and Th17 responses. E-cadherin+ BM-DCs derive from inflammatory Gr1+ monocytes and express Gr1 [3]. Blood-derived Gr1+ inflammatory DCs can induce a Th1 response to infection in vivo [19]. Here, CD40-mediated inflammatory E-cadherin + DCs promoted the Th1 response, whereas Th2 responses were decreased when these
DCs were carrying the CEA antigen peptide. As IFN-γ and IL-12 dominate, the enhanced Th1 response can inhibit Th2 cell development through a reduction in IL-4 expression [20]. The Th1 response promotes host responses to tumours because IFN-γ and IL-2 can prime the CD8+ T cell response, thereby protecting the host by monitoring against tumour development [21-23]. Nevertheless, the effect of the Th2 response on the tumour is controversial. In the 1990s, IL-4 was identified as a potent anti-tumour factor [24]. Recently, the Th2 response has been considered a factor promoting tumour growth that affects CD8+ T cells. IL-4 was found to stimulate CD8+ T cells to differentiate into non-lytic CD4+CD8+ T cells and to reduce the susceptibility of human CD8+ T cells to activate induced cell death [25].

The effect of inflammatory E-cadherin+DCs to the balance of Th17/Treg is unknown in tumour immune microenvironment. As is well-known that Treg cells contribute to...
the progression of cancer by suppressing antitumor immunity [26,27]. Even though it is protective factors in colitis, with suppressive functions through IL-10 and FOXP3 [28]. Inflammatory E-cadherin + DCs from the CD4+ CD45R+B^high T cell model demonstrate a potent ability to induce T cell-mediated colitis with Th17 responses; the effect on Treg cells was not significant with E-cadherin-DCs [3]. However, we found that CD40-mediated E-cadherin + DCs enriched the Th17 response and significantly inhibited the Treg response when the DCs were carrying the CEA peptide. Treg-mediated suppression is a crucial component of CD8^+ T cell repopulation [29]. Th17 cells are related to IL-17 and mediated by Th17-stimulated CD8^+ T cells in the induction of preventive and therapeutic antitumor immunity [30]. However, IL-17 and IL-23 have been found to drive tumour growth in colorectal cancer with Th17-mediated intestinal inflammation [31]. With Treg cell development impaired by E-cadherin^+ DCs and the increased number of Th17 cells, CEA-specific CD8^+ T cell responses are enhanced in the in vivo lung tumour model. Tumour volume decreased, and the survival time of tumour-bearing mice was prolonged significantly following the injection of CD40-mediated inflammatory E-cadherin^+ DCs compared with injection of E-cadherin^- DCs. These results may be relevant to the comprehensive effects of Th1 and Th17 on the proliferation of tumour antigen-specific CD8^+ T cell responses. The promotion of tumour growth by CD4^+ helper T cells and CD8^+ T cells is subdued with the intervention of CD40-mediated inflammatory E-cadherin^+ DCs. In particular, as the CD40 signalling pathway is activated, the expression of CD40 in the E-cadherin^+ DCs is upregulated, and naive CD4^+ and CD8^+ T cells are primed because helper T cells and the generation of CTLs by cross-priming are mediated by signalling through CD40 on the antigen-presenting cell [32].

Interestingly, the results of transferring CD40-mediated E-cadherin^+ DCs into the Lewis lung tumour model suggest that the development of helper T cells in vivo is similar to that in the in vitro experiments. Furthermore, the tumour-specific CD8^+ T cell responses were significantly enhanced following the addition of E-cadherin^+ DCs carrying CEA in vivo. Additionally, when E-cadherin^+ DCs were cultured with naïve CD8^+ T cells, the production of IFN-γ was greater than when E-cadherin^- DCs were used (Additional file 1: Figure S3). In the Th1 response, CD8 cytotoxic-T cell responses increased, Treg responses decreased, and the tumour volume was decreased. CD40-mediated inflammatory E-cadherin^+ DCs therefore possess an excellent antitumour ability via enhancement of the anti-tumour T cell response and suppression of Treg cell development. Recently, CD103^+CD8^+ T cells have been shown to be effective in inhibiting breast cancer and glioma progression. These CD103^+CD8^+ T cells can also

![Figure 5](image-url)

**Figure 5** Therapeutic efficacy of E-cadherin + DCs on lung tumour-bearing mice. (A) Changes in the tumour size in subcutaneous lung tumour-bearing mice. The tumour diameters (width*length) were measured using callipers every 2–3 days for the subcutaneous tumour model after E-cadherin + DCs were injected (each group n = 11). The mean size of the subcutaneous tumours of the mice that developed tumours in each group after tumour challenge. Three individual mice per group were analysed. In the E-cadherin + DC group, tumour volume decreased significantly compared with the E-cadherin- DC group. In the E-cadherin + DC and E-cadherin- DC groups, tumour volume increased slower than in the PBS group. (B) Survival curves of the subcutaneous tumour-bearing mice (each group n = 11). The E-cadherin + DC groups survived longer than the E-cadherin- DC groups, and both the E-cadherin + DC and E-cadherin- DC group survived longer than the PBS group. (C) Survival curves of the orthotopic lung tumour-bearing mice (each group n = 9). The E-cadherin + DC group survived longer than the E-cadherin- DC group, and both the E-cadherin + DC and E-cadherin- DC groups survived longer than the PBS group. Each experiment was performed in triplicate. The data were analysed by Student’s t-test (^p < 0.05, **p < 0.01, ***p < 0.001).
upregulate CD8+ T cell cytotoxic mediators when in contact with their specific antigen. CD103+CD8+ T cells also contribute to protecting the human lung against viral infection by producing IFN-γ and other Th1 cytokines, such as IL-2. In addition, these cells have an effector or memory phenotype [33]. In our vivo experiments, we demonstrated that E-cadherin + DCs are able to enhance the development and accumulation of CD103+CD8+ T cells. The ligand for CD103 is E-cadherin; thus, E-cadherin-expressing DCs are more likely to be recognised and combined by CD103+CD8+ T cells during antigen peptide capture, thereby activating these CD8+ T cells.

Conclusions
Taken together, these results strongly suggest that Anti-CD40-induced inflammatory E-cadherin + DCs promote T cell responses and antitumour activity in murine Lewis lung carcinoma. It is unknown why inflammatory E-cadherin+ DCs accumulate in the presence of CD40 signalling pathway activation only in innate immunity. A further understanding of the mechanisms of CD40 signalling pathway-mediated inflammatory E-cadherin+ DC differentiation in innate immunity and the tumour microenvironment may provide novel therapeutic strategies and insight into the pathogenesis of NSCLC.

Additional file

Additional file 1: Supplementary material. Figure S1. Purities of the pre-sorted and after-sorted CD40-mediated inflammatory E-cadherin+ DCs. Figure S2. Purities and phenotypes of pre-sorted and after-sorted naive CD4+ T cells and naive CD8+ T cells. Figure S3. The secretion of IFN-γ of E-cadherin+DCs group and E-cadherin-DCs group that had cultured with naive CD8+T cells respectively. Figure S4. Purified agonist CD40 antibody and established anti-CD40 model. Figure S5. The effect of inflammatory E-cadherin+DCs on CEA-specific CD8+ T cell responses in an orthotopic lung tumour model [34,35].

Competing interest
The authors declare that they have no competing interest.

Author contributions
LL conceived and designed the experiments. YZ, XYH, YH, KT and YW performed the experiments. YMZ, XHH and KZ analysed the data. YZ and XYH, YH, KT and YW conceived and designed the experiments. YZ, XYH, YH, KT and YW collected the data. LL, LM, LG and YW critically revised the manuscript. All authors read and approved the manuscript.

Acknowledgements
We thank Pr. Antonius Rolink (Basel Institute for Immunology, Basel, Switzerland) for providing the FGG45 cells and the mouse anti-mouse CD40 antibody. This work was supported by 2 grants from the National Natural Science Foundations of China (81711797, 81372260) and 1 grant from Doctoral fund (2011042110005).

Author details
1Cancer Center, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, 156 Wujiadun, Wuhan 430023, Hubei, China. 2Hainan Cancer Hospital, Haikou, Hainan, China. 3Department of oncology, Central Hospital of Wuhan, Wuhan, Hubei, China. 4Laboratory of Cardiovascular Immunology, Institute of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China. 5Institute of Hydro Biology, Chinese Academy of Sciences, Analysis and Testing center, Wuhan, China.

Received: 6 November 2014 Accepted: 19 January 2015
Published online: 05 February 2015

References
1. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19:1035–43.
2. Richman UP, Vonderheide RH. Role of crosslinking for agonisticCD40 monoclonal antibodies as immune therapy of cancer. Immunol Res. 2014;2:19–26.
3. Siddiqui KR, LaFont S, Powrie F. E-cadherin marks a subset of inflammatory dendritic cells that promote T cell-mediated colitis. Immunity. 2010;32:557–67.
4. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003;10:1–13.
5. Kedi RM, Jordan M, Potter T, Kappler J, Marrack P, Dow S. CD40 stimulation accelerates deletion of tumour-specific CD8(+) T cells in the absence of tumour-antigen vaccination. Acad Sci USA. 2007;98:811–6.
6. Bernet V, Liu H, Zhou Q, Alderson KL, Sun K, Weiss JM, et al. IFN-gamma mediates CD4+ T cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med. 2007;13:594–60.
7. Chiocioni C, Iezzi M, Guiducci C, Sangalletti S, Alessandri J, Ratti C, et al. Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med. 2006;203:2441–50.
8. Bergmann S1, Pandolfi PP. Giving Blood: a new role for CD40 in tumorigenesis. J Exp Med. 2006;203:2409–12.
9. Coombs JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxt3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007;204:1757–64.
10. Eramo A, Lotti T, Sette G, Pilozi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504–14.
11. Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol. 2000;165:779–85.
12. Wu TC, Xu K, Banchereau R, Marches F, Yu CL, Martinek J, et al. Reprogramming tumor-infiltrating dendritic cells for CD103+ CD8+ mucosal T-cell differentiation and breast cancer rejection. Cancer Immunol. 2014;2:487–500.
13. Iouannneau E, Black XL, Vega L, Gordner R, Govershanda S, Zhai Y, et al. Intrinsically desialylated CD103+ CD8 T cells mediate beneficial anti-glioma immune responses. Cancer Immunol Immunother. 2014;63:911–24.
14. Hespel C, Moser M. Role of inflammatory dendritic cells in innate and a captive immunity. Eur J Immunol. 2012;42:2535–43.
15. Leon B, Lopez-Blazo M, Ardavin C. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity. 2007;26:519–31.
16. Inaba K, Pack M, Inaba M, Sakuta H, Issell F, Steinman RM. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med. 1997;186:665–72.
17. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A. 1999;96:1036–41.
18. D De Smedt T, Michel P, Godfroid J, Pajak B, Heiman C, Thielemans K, et al. CD80+ and CD80+ subclasses of dendritic cells direct the development of distinct helper T cells in vivo. J Exp Med. 1999;189:387–92.
19. Nakano H, Liu KL, Yanagita M, Charbonneau C, Cook DN, Kakuchi T, et al. Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses. Nat Immunol. 2009;10:394–402.
20. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787–93.
21. Dighe AS, Richards E, Old LJ. Schreiber RD:Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN receptors. Immunol. 1994;1:447–56.
22. Ekens MJ, Shedlock DJ, Jung E, Troy A, Pearce EL, Shen H, et al. Th1 and Th2 cells help CD8 T-cell responses. Infect Immun. 2007;75:2291–6.
23. Maria S, Paola Cordiali F, Luana F, Maria Bena M, Claudia C, Michelle G, et al. Immunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical cystectomy: preliminary results. J Exp Clin Cancer Res. 2013;32:6.
24. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989;57:503–12.

25. Rou C, Dumont AR, Yassine-Diab B, Haddad EK, Sekaly RP. IL-4 influences the differentiation and the susceptibility to activation-induced cell death of human naive CD8+ T cells. Int Immunol. 2006;18:827–35.

26. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295–307.

27. Wei S, Wei-Jin L, Chang-You W, Hua Z, Wei-Ping W. CD45RA+Foxp3high but not CD45RA−Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression. J Exp Clin Cancer Res. 2014;33:35.

28. Muts M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol. 2009;10:1178–84.

29. Almeida AR, Cemik IF, Sallusto F, Lanzonechacchia A. CD4+CD25+ Treg regulate the contribution of CD8+ T-cell subsets in repopulation of the lymphopenic environment. Eur J Immunol. 2010;40:3478–88.

30. Ankathatti Munegowda M, Deng Y, Mulligan SJ, Xiang J, Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol Immunother. 2011;60:1473–84.

31. Gryneninov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491:254–8.

32. Bennett SB, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478–80.

33. Piet B, de Bree GJ, Smids-Dierdorp BS, van der Loos CM, Remmerswaal EB, von der Thuisen JH, et al. CD8+ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J Clin Invest. 2011;121:2254–63.

34. Han Y, Guo Q, Zhang M, Chen Z, Cao X. CD69+CD4+CD25+ T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-β. J Immunol. 2009;182:111–20.

35. Gratton JP, Lin ML, Yu J, Weiss ED, Jiang ZL, Fairchild TA, et al. Selective inhibition of tumor microvascular permeability by cavitra mixes blocks tumor progression in mice. Cancer Cell. 2003;4:31–9.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit